165 related articles for article (PubMed ID: 4257247)
1. Parkinsonism-dementia of Guam: treatment with L-dopa.
Schnur JA; Chase TN; Brody JA
Neurology; 1971 Dec; 21(12):1236-42. PubMed ID: 4257247
[No Abstract] [Full Text] [Related]
2. Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid.
Chase RN; Schnur JA; Brody JA; Gordon EK
Arch Neurol; 1971 Jul; 25(1):9-13. PubMed ID: 5146413
[No Abstract] [Full Text] [Related]
3. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
van Woert MH; Bowers MB
Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
[No Abstract] [Full Text] [Related]
4. Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam.
Brody JA; Chase TN; Gordon EK
N Engl J Med; 1970 Apr; 282(17):947-50. PubMed ID: 5436031
[No Abstract] [Full Text] [Related]
5. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
Johansson B; Roos BE
Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
[No Abstract] [Full Text] [Related]
6. L-Dopa treatment in Parkinson's Disease.
Rinne UK; Sonninen V; Siirtola T
Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
[No Abstract] [Full Text] [Related]
7. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.
Godwin-Austen RB
J Neurol Neurosurg Psychiatry; 1971 Jun; 34(3):219-23. PubMed ID: 5571307
[TBL] [Abstract][Full Text] [Related]
8. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
[No Abstract] [Full Text] [Related]
9. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
Gumpert J; Sharpe D; Curzon G
J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
[No Abstract] [Full Text] [Related]
10. Treatment of Parkinson's disease with amantadine and L-Dopa.
Rinne UK; Sonninen V; Siirtola T
Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
[No Abstract] [Full Text] [Related]
11. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
Casati C; Agnoli A; Jori A; Dolfini E
Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
[No Abstract] [Full Text] [Related]
12. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
Chase TN
Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
[No Abstract] [Full Text] [Related]
13. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism.
Gottfries CG; Gottfries I; Roos BE
J Neurochem; 1969 Sep; 16(9):1341-5. PubMed ID: 5808100
[No Abstract] [Full Text] [Related]
14. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
[No Abstract] [Full Text] [Related]
15. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
Rinne UK; Sonninen V; Siirtola T
Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
[No Abstract] [Full Text] [Related]
16. Treatment of parkinsonism with L-dopa (study of 105 patients).
Klawans HL; Garvin JS
Dis Nerv Syst; 1969 Nov; 30(11):737-46. PubMed ID: 5359046
[No Abstract] [Full Text] [Related]
17. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
[No Abstract] [Full Text] [Related]
18. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
van Woert MH; Bowers MB
Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
[No Abstract] [Full Text] [Related]
19. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
Chase TN; Watanabe AM
Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
[No Abstract] [Full Text] [Related]
20. Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
Holden EM; Brody JA; Chase TN
Neurology; 1974 Mar; 24(3):263-5. PubMed ID: 4855953
[No Abstract] [Full Text] [Related]
[Next] [New Search]
